Merz Aesthetics® Receives Approval from Health Canada for RADIESSE® as an Aesthetic Injectable for the Treatment of Moderate Wrinkles in the Décolleté Area
Article content
BURLINGTON, Ontario — Merz Aesthetics ® Canada announced today the Health Canada approval for Radiesse ® for the treatment of moderate wrinkles in the décolleté area. Radiesse ® is a regenerative biostimulator 1 capable of regenerating multiple components of the skin tissue, resulting in healthier-looking skin, 1,4,5 and is now approved for use in the décolleté area, adding to the product's versatility.
Article content
This new regulatory milestone directly answers patient demand, given there is a significant shift toward regenerative biostimulation.
Article content
'Despite being one of the most visible areas of our bodies, the décolleté area is often overlooked when it comes to aesthetics,'
Article content
says Dr. Samantha Kerr, Chief Scientific Officer, Merz Aesthetics
Article content
®
Article content
.
Article content
'Radiesse ® presents a unique solution to improving décolleté wrinkles and provides our customers and their patients a non-surgical, effective option to address aging décolleté skin.'
Article content
According to the International Society of Aesthetic Plastic Surgery (ISAPS), non-surgical procedures/minimally invasive treatments between 2018 and 2022 involving calcium hydroxylapatite increased by 171.8% globally between 2018 and 2022. 2 This approval was supported by a large, multicentre clinical trial 3,5,1 which supported the décolleté approval and has provided substantial evidence of the effectiveness of Radiesse ®, demonstrating a significant improvement in the appearance of moderate décolleté wrinkles. 3 ' The décolleté is notoriously difficult to treat. Skin in this area is thin, chronically sun-exposed, low in sebaceous glands, prone to accelerated loss of elasticity, and tends to form more complex scars than other regions. Health Canada's new approval of Radiesse® for this area is therefore exciting and welcome news. It is a true biostimulator that has almost 20 years of safety data for the face, and an agent we turn to regularly in our clinic for this area. So, it is great to be able to officially use this amazing product on the décolleté as well. The biostimulatory effects work by triggering collagen, elastin, and micro-vasculature renewal, thickening the tissue and softening lines. It is a powerful treatment that gives natural-looking radiant results. This new approval now gives us a proven, regenerative tool to rejuvenate the skin on the chest, ' says Dr. Dusan Sajic, a leading Canadian medical and cosmetic dermatologist.
Article content
This year Radiesse ® celebrates its 20 th anniversary, having sold more than 15 million syringes globally since 2005. 3 Merz Aesthetics demonstrates a longstanding legacy and commitment to scientific innovation in the aesthetics field. 3 After two decades on the market, the new décolleté indication allows practitioners more versatility to expand the treatment spectrum from the face and hands to treatments for the décolleté. Additionally, the 1:2 dilution with 0.9% sterile saline increases the product adaptability allowing for personalized treatment to address patient needs.
Article content
'This new indication for Radiesse ® to treat the décolleté area marks a significant milestone for the aesthetics market,'
Article content
.
Article content
'It not only expands the versatility of Radiesse ® but also addresses a growing patient demand for regenerative aesthetic solutions. By offering a proven, effective treatment for décolleté wrinkles, we are enhancing our commitment to innovation and patient care. This approval underscores our dedication to providing advanced, minimally invasive options that cater to the evolving needs of our patients.'
Article content
Even in the current landscape, findings from Medical Insight's 2024 Global Aesthetic Market Study suggest that Radiesse ® has emerged as a category leader. 6 This success is backed by over two decades of scientific data and clinical experience by Merz Aesthetics ®, 4,2 with 250 publications, 3 and availability in over 85 countries. 3 About Merz Aesthetics ® Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients, and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient's needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics' global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contacts
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 minutes ago
- Globe and Mail
Keyera Announces Sanctioning of KAPS Zone 4 and Provides Other Commercial Updates
CALGARY, AB , /CNW/ - Keyera Corp. (TSX: KEY) ("Keyera") announced today the formal sanctioning of KAPS Zone 4, a strategic extension of its integrated system. This expansion strengthens Keyera's connectivity to the growing liquids-rich Montney regions of northeast British Columbia and northwest Alberta , some of the most active and resource-rich areas in North America . "The sanctioning of KAPS Zone 4 marks another important milestone in the execution of our strategy to grow and extend our value chain," said Dean Setoguchi , President and CEO. "This project reflects strong customer demand for our fully integrated service offerings and our ability to connect to valuable end-markets. By enhancing connectivity and optionality, Zone 4 strengthens our competitive position and delivers greater value to our customers." KAPS Zone 4 is an 85-kilometre extension of the existing KAPS pipeline, connecting Pipestone to Gordondale, Alberta . It will connect to NorthRiver Midstream's Northeast BC Connector project. Together, these systems offer Montney producers a fully integrated and cost-effective route from northeast British Columbia to Fort Saskatchewan area fractionation and Keyera's industry-leading condensate hub. The capital cost of KAPS Zone 4 is expected to be $220 million (net to Keyera), which includes investments in additional pumping capacity on KAPS Zones 1 to 3. The project is targeted to enter service in mid-2027. The project is backed by long-term transportation agreements with several investment-grade Montney producers, averaging 11 years in duration and 75% take-or-pay commitments. The agreements include downstream services such as fractionation, storage, transportation, and marketing, further demonstrating the value of Keyera's integrated offering. Keyera has secured over 75,000 barrels per day of new contracted volumes across KAPS Zones 1 through 4 in recent months, with substantially all volumes also committed to incremental downstream services. Keyera's current and future fractionation capacity, which includes the Fort Saskatchewan Fractionation Unit II debottleneck and the Fort Saskatchewan Fractionation Unit III expansion project, is now substantially fully contracted, supporting strong utilization and returns across the system. Investments in Zone 4 and fractionation expansions directly contribute to the growth of Keyera's long-term, fee-for-service cash flows, supporting continued sustainable dividend growth. In response to growing volumes across Keyera's integrated system, Keyera has entered into an agreement with AltaGas to export an additional 12,500 barrels per day of natural gas liquids via AltaGas' west coast export facilities starting in 2028. This builds on the 12,500 barrels per day announced earlier this year. The agreement will further strengthen Keyera's ability to offer its customers more diversified market access for LPGs, including premium Asian markets, while providing AltaGas with long-term ratable export volumes and cash flows. About Keyera Corp. Keyera Corp. (TSX: KEY) operates an integrated Canadian-based energy infrastructure business with extensive interconnected assets and depth of expertise in delivering energy solutions. Its predominantly fee-for-service based business consists of natural gas gathering and processing; natural gas liquids processing, transportation, storage and marketing; iso-octane production and sales; and an industry-leading condensate system in the Edmonton / Fort Saskatchewan area of Alberta . Keyera strives to provide high quality, value-added services to its customers across North America and is committed to conducting its business ethically, safely and in an environmentally and financially responsible manner. Forward-Looking Statements This news release contains certain statements that constitute forward-looking information within the meaning of applicable Canadian securities legislation (collectively, "forward-looking information"). Forward-looking information is typically identified by words such as "anticipate", "expect", "may", "will", "can", "should", "would", "plan", "intend", "believe", "target", and similar words or expressions, including the negatives or variations thereof. All statements other than statements of historical fact contained in this document are forward-looking information including, without limitation, statements regarding the cost and timing of the KAPS Zone 4 project; the impact of this project on Keyera's stand-alone project return on capital target; the results of additional contracting discussions with third parties and the expected impact on future volumes on KAPS; and expectations around the impact of the agreement with AltaGas on market access. All forward-looking information is based on a number of risks, expectations, assumptions and uncertainties that Keyera has used to develop such information, but which may prove to be incorrect. Such risks, expectations, assumptions and uncertainties include, without limitation, general industry, market and economic conditions; activities of customers, producers and other facility owners; actions by joint venture partners or other partners which hold interests in certain of Keyera's assets; counterparty performance and credit risk; reliance on third parties; actions by governmental authorities; and the ability to obtain regulatory, stakeholder and third-party approvals. Further information about the factors affecting forward-looking information and management's assumptions and analysis thereof, is available in Keyera's Management's Discussion and Analysis for the year ended December 31, 2024 and in Keyera's Annual Information Form available on Keyera's profile on SEDAR+ at While Keyera believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because Keyera can give no assurance that such expectations will prove to be correct. Readers are cautioned that the foregoing list of important factors is not exhaustive, and they should not unduly rely on the forward-looking information included in this press release. Further, readers are cautioned that the forward-looking information contained herein is made as of the date of this press release. Unless required by law, Keyera does not intend and does not assume any obligation to update any forward-looking information. All forward-looking information contained in this press release is expressly qualified by this cautionary statement. Additional Information For more information about Keyera Corp., please visit our website at or contact: Dan Cuthbertson , General Manager, Investor Relations Katie Shea , Senior Advisor, Investor Relations
National Post
15 minutes ago
- National Post
The Society of United Professionals to Join WSIB Strike Picket Line, Marking 20th Anniversary of Historic Society Strike
Article content TORONTO — Members of the Society of United Professionals, IFPTE Local 160, will join the ongoing picket line at 200 Front Street West on Monday, June 9, 2025, in support of 3,600 striking WSIB workers represented by the Ontario Compensation Employees Union (OCEU/CUPE 1750). This show of solidarity comes as OCEU recently marked two weeks on strike, demanding fair wages, safer workplaces, and an end to outsourcing critical Ontario jobs to U.S. firms. Article content Approximately 170 Society members, will walk the picket line alongside OCEU/CUPE 1750 members. The action coincides with the 20th anniversary of the Society's own 105-day strike at Hydro One—a pivotal moment in Ontario's labour history. Article content Speakers at a 10:00 a.m. rally will include: Article content 'Ontario's public sector workers are united in their call for respect, fair pay, and safe working conditions,' Matt Biggs, International President of the Society of United Professionals. 'We know firsthand the challenges of standing up for what's right, and we're proud to stand shoulder to shoulder with OCEU/CUPE 1750 members as they fight for all Ontarians.' Article content Since the walkout began, WSIB staff have faced chronic understaffing, stagnant wages, and increased pressure to outsource vital services. The ongoing strike highlights the urgent need for government and management to invest in Ontario jobs and public services, rather than sending work south of the border. Article content 'We're incredibly grateful to the Society of United Professionals and IFPTE for standing with us on the picket line,' said Harry Goslin, President of OCEU/CUPE 1750. 'Their solidarity sends a powerful message—not just to our employer, but to the entire labour movement—that when workers stand together, we are stronger, louder, and impossible to ignore.' Article content A small Society delegation will also attempt to deliver a letter of solidarity on behalf of 90,000 IFPTE members across North America to WSIB President Jeffery Lang, underscoring growing concern over the Ford government's inaction on dangerous workloads and the outsourcing of Ontario jobs. Article content Article content Article content Article content Article content Article content Article content
National Post
17 minutes ago
- National Post
Derek Finkle: Pro-drug injection site activists were dangerously wrong on closures
'A lot more people are going to die.' Article content This was the dire prediction oft-repeated back in March by a busload of lawyers who supported a legal challenge filed by an injection site in Toronto that claimed recent Ontario legislation forcing the closure of sites within 200 metres of schools and daycare facilities violates the Charter rights of drug users. Article content The two expert witnesses for that site, in the Kensington neighbourhood of Toronto, are employed by the MAP Centre for Urban Health Solutions, a hospital-run research centre. MAP had played a key role in the establishment of the city's first injection sites in 2017. Dr. Ahmed Bayoumi and Dr. Dan Werb both submitted evidence that overdose deaths in Toronto would increase sharply if half of the city's ten injection sites closed at the end of March because of the legislation. Article content Fred Fischer, a lawyer representing Toronto's Board of Health, one of the intervenor groups in the case, also told Justice John Callaghan of the Ontario Superior Court that reducing harm reduction services in Toronto during the ongoing opioid crisis would have severe consequences — more people will overdose and die. Article content Article content A lawyer for another intervenor, a harm reduction coalition, put an even finer point on it. He said that one of the Toronto injection sites not affected by the legislation was anticipating such an immediate and overwhelming increase in overdose deaths in April, after the closures, that the site was in the process of hiring grief counsellors for its staff. Article content More than two months have passed since then, and now that we're in June, you might be wondering: How many more people ended up dying because of the closure of these sites? Article content According to data that's compiled by Toronto Paramedic Services and Toronto Public Health, the answer, so far, is none. In fact, the number of overdoses in Toronto for the month of April, the first month after the sites had closed, dropped notably. Article content Article content Toronto had 13 fatal overdose calls in April, one less than in March, when the now-closed injection sites were still open. Thirteen is less than half the number of fatal overdoses across the city in April of last year, and significantly below the monthly average for all of 2024 (19). Article content Article content Thirteen fatal overdoses are far lower than the average monthly number during the period of Covid-19 emergency between April 2020 and May 2023 (25). The last time 13 was the norm for monthly fatal overdoses was prior to the pandemic. Article content The number of calls for non-fatal overdoses in April was 161. This may sound like a lot but it's the lowest monthly total so far this year in Toronto. And 161 non-fatal overdoses are 55 per cent less than the 359 that occurred in April of 2024. Article content Remarkably, in the third week of April, there were zero fatal overdose calls, something that hasn't happened in Toronto in months.
